Undisclosed bispecific program no. 2 / Alligator Biosci, Orion Corp - LARVOL DELTA

Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement (Alligator Bioscience Press Release) - "Alligator Bioscience...today announces that Orion Corporation, a global pharmaceutical company based in Finland, has selected the lead bispecific antibodies from the companies’ second development program, and is exercising its option to develop these molecules under the existing 2021 research collaboration and license agreement. The exercise of this development option triggers an undisclosed milestone payment to Alligator....Under the initial agreement signed in August 2021, Alligator employed its proprietary phage display libraries and RUBY bispecific antibody format to develop immuno-oncology product candidates based on design criteria identified by Orion. In January 2023, the agreement was expanded to include the development of a second bispecific antibody. Alligator is eligible for development, approval and sales milestone payments in addition to royalties if Orion continues developing and commercializing the resulting product candidates."

Licensing / partnership • Oncology